Big News!

We are thrilled to announce that our white paper of the 2019 Kidney Cancer Research Summit (KCRS) was just published in the Journal of the National Cancer Institute. You can see the paper here.

The paper highlights the ground-breaking translational research performed by Department of Defense-funded researchers as part of the Congressionally-Directed Medical Research Programs, specifically the Kidney Cancer Research Program.

What This Means

This white paper summarizes amazing work from translational researchers all over the country that are moving the field of kidney cancer research forward.
Epigenetics, novel drugs, immune microenvironment, rare kidney cancer variants, and other topics were covered at this event.

While KCRS19 stimulated discussion on important kidney cancer research challenges, there is a lot more we need to work on as a field as we look forward to KCRS20 this fall — whether our planned event unfolds in person or virtually.

For example, KCRS19 addressed a range of important topics — novel molecular targets for the treatment of RCC, improving drug delivery methods to improve cell specificity, state-of-the-art sequencing methods, finding novel immune checkpoints (beyond PD-(L)1 and CTLA-4), improving the characterization of molecular drivers of variant histiology, and improving collaborations between clinicians and scientists.

Looking forward to KCRS20, we still have to address a number of unmet needs: developing representative cell line models of different renal cell histologies, leveraging novel methods to target transcriptional factors in RCC, better recognizing and tailoring the management of hereditary cancer conditions associated with RCC, novel therapeutic options for variant histology RCC subtypes, and better defining the clonal evolutional history of renal cell carcinoma tumors.

Why This Matters

Until the KidneyCAN team produced KCRS in 2019, there had not been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. A group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma (RCC) launched KCRS to spur collaboration and further therapeutic advances in these tumors.

The white paper published by JNCI provides a summary of KCRS. For the laypeople among us, it is heavy on science and perhaps difficult to understand. However, we feel confident that you will share our satisfaction and hope at seeing the growth and cohesion of a talented community focused on kidney cancer.

KidneyCAN extends our sincerest thanks to the many fine researchers who support and contribute to the understanding, the treatment and the progress toward a cure. We extend our special thanks to our Co-Chairs Dr. Toni Choueiri and Dr. Hans Hammers, who give so much time to support this vision to bring researchers together to collaborate on a cure.

 

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Deb Beyhan is the Patient Legislative Advocate for KidneyCAN. She was diagnosed with stage IV kidney cancer in 2016 at the age of 53. Deb lives outside of Atlanta, GA, with her husband.    For this month's Community Spotlight, we want to tell you about a member of our volunteer team, Deb Beyhan....

DISTRICT DAYS 2022 →

SPRING ADVOCACY DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

District Days: Asking Congress to Fund Kidney Cancer Research

District Days: Asking Congress to Fund Kidney Cancer Research

On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

The 2022 Kidney Cancer Research Summit

The 2022 Kidney Cancer Research Summit

Dr. Laurence Albiges (Institut Gustave Roussy) presents on the microbiome at KCRS22. The microbiome has now been recognized as one of the emerging hallmarks and enabling characteristics of cancer. KidneyCAN hosted the 4th Annual Kidney Cancer Research Summit on October 6-7, 2022  live in...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Rock the Run for Kidney Cancer Research Funding

Rock the Run for Kidney Cancer Research Funding

KidneyCAN had the first ever Rock the Run 5k fundraiser in October 2022. This is part of the group of KCRS22 attendees who walked and ran with us at dawn before the second conference day began. KidneyCAN is proud to share the results of the first annual Rock the Run 5K fundraiser. Our Purpose...